Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
recMAGE-A3 + AS15 ASCI in MAGE-A3 Positive Muscle Invasive Bladder Cancer After Cystectomy
NCT01435356Phase 2Terminated
- Sponsor
- EAU Research Foundation
- Start
- Aug 2011
- Primary completion
- Apr 2017
- Modality
- Vaccines & Immunotherapeutics, Peptides, Fc-Fusion Proteins
- Countries
- 10
01
Overview
Phase 2, randomised, double-blind trial in muscle-invasive bladder cancer (MIBC) comparing recMage-A3 + AS15 ASCI with Placebo (2 arms). Primary endpoint: Disease Free Survival at 5 years. Started Aug 2011; status: terminated.
02
Drugs
astuprotimut-R
03
Conditions
muscle-invasive bladder cancer (MIBC)
Beyond the preview
Go deeper on NCT01435356.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01435356.